Core Viewpoint - Idorsia Ltd is positioned for profitability and growth with two products entering the value-acceleration phase and a promising pipeline of innovative medicines [2][3] Highlights in 2025 - Idorsia achieved strong operational progress, including the global expansion of QUVIVIQ, which is on track to meet sales guidance of approximately CHF 130 million [7] - The company completed debt restructuring and secured new financing, extending its cash runway into 2028 [7] - Clinical validation for its synthetic glycan vaccine technology and initiation of a proof-of-concept trial with a CCR6 antagonist were also notable achievements [7] Areas of Focus in 2026 - The company aims to make QUVIVIQ the standard of care for insomnia and maximize the value of TRYVIO/JERAYGO for uncontrolled hypertension [3][7] - Plans include advancing lucerastat for Fabry Disease registration and progressing the Phase 2 proof-of-concept immunology portfolio [7] - Idorsia will continue to explore partnerships and new sales models for QUVIVIQ, as well as support potential descheduling in the US [7]